Symptomtext
multiple excurion occured during shiping time with no adverse event; Initial information received on 16-Sep-2021 regarding an unsolicited valid non-serious case received from a other health care profession and non-healthcare professional via Medical Information under reference - 00773210. This case involves a unknown age of 13 female patient's were vaccinated INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] which went on multiple temperature excursions (product storage error). The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided. No concomitant therapy was given. On an unknown date, the patient's received a 0.7 mL (total) dose of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot - UJ716AB and expiry date 30-06-2022) via an unknown route at an unknown administration site for prophylactic vaccination. It was reported "The caller stated that she was contacted by a Sanofi Rep who advised her that her recent shipment of FLUZONE HIGH DOSE QUADRIVALENT was not viable. The caller stated that she has already contacted Sanofi regarding a product replacement, as directed by her Sanofi Rep. The caller stated that the product was shipped on 02 SEP 2021 and received on 07 SEP 2021. The caller stated that 13 patients have received the vaccine since delivery. At this time, the caller is requesting medical information for the proper care for the 13 patients who received the vaccine. Note from Agent; At the time of the call back the clinic did not have the information for the patients that received the vaccines." It was a case of a actual medication error due to incorrect product storage. At the time of reporting, no adverse event reported. Outcome of event was unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.